Immunovant
IMVT
186 hedge funds and large institutions have $2.04B invested in Immunovant in 2024 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 68 increasing their positions, 61 reducing their positions, and 29 closing their positions.
305% more call options, than puts
Call options by funds: $73.9M | Put options by funds: $18.2M
31% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 29
11% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 61
3% more funds holding
Funds holding: 181 → 186 (+5)
1.96% more ownership
Funds ownership: 54.1% → 56.06% (+2%)
10% less capital invested
Capital invested by funds: $2.26B → $2.04B (-$220M)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AGM
Alpine Global Management
New York
|
+$69.1M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$50.7M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$46.9M |
| 4 |
JP Morgan Chase
New York
|
+$26.2M |
| 5 |
TSC
Two Seas Capital
Rye,
New York
|
+$23.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
-$38.9M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$27.8M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$25.9M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$22.7M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$21.9M |
IMVT Hedge Fund Activity: Q4 2024 in Review
186 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q4 2024, worth a combined $2.04B — down 9.7% from $2.26B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new IMVT positions and 29 closed out — a net gain of 9 holders — while 68 added to existing stakes and 61 trimmed.
The largest buyer was Alpine Global Management, adding an estimated $69.1M. The largest seller was Paradigm Biocapital Advisors, exiting entirely with an estimated $38.9M sold.
- 186 institutional investors held Immunovant (IMVT) as of Q4 2024, up from 181 in Q3 2024.
- Funds reported $2.04B of Immunovant stock for Q4 2024, down 9.7% quarter-over-quarter.
- 38 funds opened new Immunovant positions in Q4 2024 and 29 closed out, a net change of +9 holders.
- The largest Immunovant buyer in Q4 2024 was Alpine Global Management, an estimated $69.1M added.
- The largest Immunovant seller in Q4 2024 was Paradigm Biocapital Advisors, an estimated $38.9M sold.
Based on aggregated 13F filings for Q4 2024.